LV12108B - IMPORTANT DERIVATIVES FOR ALFA-2 RECEPTORS - Google Patents

IMPORTANT DERIVATIVES FOR ALFA-2 RECEPTORS Download PDF

Info

Publication number
LV12108B
LV12108B LVP-98-61A LV980061A LV12108B LV 12108 B LV12108 B LV 12108B LV 980061 A LV980061 A LV 980061A LV 12108 B LV12108 B LV 12108B
Authority
LV
Latvia
Prior art keywords
hydrogen
alkyl
nmr
derivative according
imidazole
Prior art date
Application number
LVP-98-61A
Other languages
English (en)
Latvian (lv)
Other versions
LV12108A (lv
Inventor
Arto Karjalainen
Paavo Huhtala
Juha-Matti Savola
Siegfried Wurster
Maire Eloranta
Maarit Hillila
Raimo Saxlund
Victor Cockcroft
Arja Karjalainen
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of LV12108A publication Critical patent/LV12108A/xx
Publication of LV12108B publication Critical patent/LV12108B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LVP-98-61A 1995-10-03 1998-03-31 IMPORTANT DERIVATIVES FOR ALFA-2 RECEPTORS LV12108B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9520150.5A GB9520150D0 (en) 1995-10-03 1995-10-03 New imidazole derivatives
PCT/FI1996/000518 WO1997012874A1 (en) 1995-10-03 1996-10-02 Imidazole derivatives having affinity for alpha2 receptors activity

Publications (2)

Publication Number Publication Date
LV12108A LV12108A (lv) 1998-08-20
LV12108B true LV12108B (en) 1998-10-20

Family

ID=10781676

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-98-61A LV12108B (en) 1995-10-03 1998-03-31 IMPORTANT DERIVATIVES FOR ALFA-2 RECEPTORS

Country Status (30)

Country Link
US (2) US6313311B1 (cs)
EP (1) EP0888309B1 (cs)
JP (1) JP4129891B2 (cs)
KR (1) KR19990064013A (cs)
CN (1) CN1068592C (cs)
AT (1) ATE234819T1 (cs)
AU (1) AU708002B2 (cs)
BG (1) BG63916B1 (cs)
CA (1) CA2231535C (cs)
CZ (1) CZ291576B6 (cs)
DE (1) DE69626862T2 (cs)
DK (1) DK0888309T3 (cs)
EE (1) EE04436B1 (cs)
ES (1) ES2195013T3 (cs)
GB (1) GB9520150D0 (cs)
HK (1) HK1014951A1 (cs)
HU (1) HU224197B1 (cs)
IL (1) IL123721A (cs)
LT (1) LT4460B (cs)
LV (1) LV12108B (cs)
NO (1) NO311024B1 (cs)
NZ (1) NZ319169A (cs)
PL (1) PL189110B1 (cs)
PT (1) PT888309E (cs)
RO (1) RO120409B1 (cs)
RU (1) RU2188194C2 (cs)
SI (1) SI9620111B (cs)
SK (1) SK283542B6 (cs)
UA (1) UA49847C2 (cs)
WO (1) WO1997012874A1 (cs)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA981080B (en) * 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
AU2002254265B2 (en) * 1997-12-04 2008-05-15 Allergan, Inc. Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
RU2235092C2 (ru) * 1997-12-04 2004-08-27 Оллерган Инк. Замещенные производные имидазола, способ введения активного соединения и способ лечения на основе этих соединений
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
EP1117399B1 (en) * 1998-09-28 2005-02-09 Orion Corporation Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
WO2001000192A2 (en) * 1999-06-25 2001-01-04 Orion Corporation Method of administering an imidazole derivative to obtain analgesia
AU778522B2 (en) 1999-10-29 2004-12-09 Orion Corporation Treatment or prevention of hypotension and shock
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
ATE302757T1 (de) 2000-05-08 2005-09-15 Orion Corp Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität
TW200306783A (en) * 2002-04-29 2003-12-01 Fmc Corp Pesticidal heterocycles
FR2839719B1 (fr) * 2002-05-16 2004-08-06 Pf Medicament Nouveaux composes imidazoliques, leur procede de preparation et leur utilisation a titre de medicaments
FI20022159A0 (fi) * 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
DE102004035322A1 (de) * 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
RU2008110902A (ru) 2005-08-25 2009-09-27 Шеринг Корпорейшн (US) Агонисты адренорецепторов альфа а2с
KR20080039982A (ko) 2005-08-25 2008-05-07 쉐링 코포레이션 작용 선택적 알파2ｃ 아드레날린성 수용체 효능제로서의이미다졸 유도체
RU2440344C2 (ru) * 2006-01-27 2012-01-20 Ф.Хоффманн-Ля Рош Аг Применение 2-имидазолов для лечения расстройств цнс
AU2007312390B2 (en) 2006-10-19 2013-03-28 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
JP5064511B2 (ja) 2006-11-02 2012-10-31 エフ．ホフマン−ラ ロシュ アーゲー 痕跡アミン関連受容体調節剤としての置換２−イミダゾール
KR101134226B1 (ko) 2006-11-16 2012-04-10 에프. 호프만-라 로슈 아게 치환된 4-이미다졸
WO2008071574A1 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (taar)
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
JP5248528B2 (ja) 2007-02-02 2013-07-31 エフ．ホフマン−ラ ロシュ アーゲー Ｃｎｓ疾患用のｔａａｒ１リガンドとしての新規２−アミノオキサゾリン
CA2678036A1 (en) 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
US8470863B2 (en) 2007-02-13 2013-06-25 Merck Sharp & Dohme, Corp. Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists
JP2010518163A (ja) * 2007-02-13 2010-05-27 シェーリング コーポレイション 機能選択性α２Ｃアドレナリン受容体アゴニスト
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
EP2173720A2 (en) 2007-07-02 2010-04-14 F. Hoffmann-Roche AG 2-imidazolines having a good affinity to the trace amine associated receptors (taars)
BRPI0812833A2 (pt) 2007-07-03 2014-12-09 Hoffmann La Roche 4-imidazolinas e seu uso como antidepressivos
KR101133862B1 (ko) 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
AU2008285795A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as TAAR1 ligands
US8383818B2 (en) 2008-02-21 2013-02-26 Merck Sharp & Dohme Corp. Functionally selective alpha2C adrenoreceptor agonists
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
WO2010042473A1 (en) 2008-10-07 2010-04-15 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
CA2762107A1 (en) 2009-05-15 2010-11-18 Recro Pharma, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8673950B2 (en) 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) * 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
EP2787970B1 (en) 2011-12-11 2018-04-11 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
MX354815B (es) 2012-01-12 2018-03-22 Hoffmann La Roche Derivados heterociclicos como receptores asociados con las aminas traza (taars).
PL2895477T3 (pl) 2012-09-14 2018-03-30 F.Hoffmann-La Roche Ag Pochodne pirazolokarboksyamidu jako modulatory taar do stosowania w leczeniu kilku zaburzeń, takich jak depresja, cukrzyca i choroba parkinsona
ES2605632T3 (es) 2012-09-17 2017-03-15 F. Hoffmann-La Roche Ag Derivados triazol carboxamida
WO2015165085A1 (en) 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
WO2016030306A1 (en) 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted pyrazino[2,1-a]isoquinoline derivatives for the treatment of cns disorders
MX2016016488A (es) 2014-08-27 2017-03-30 Hoffmann La Roche Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar).
SG11201807516UA (en) 2016-03-17 2018-09-27 Hoffmann La Roche 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636002A (en) * 1969-12-15 1972-01-18 Janssen Pharmaceutica Nv 1-(2-halobenzyloxy-1-indanyl)-imidazoles
ES523609A0 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
US4634705A (en) * 1984-06-06 1987-01-06 Abbott Laboratories Adrenergic amidines
US4659730A (en) * 1984-06-18 1987-04-21 Eli Lilly And Company Aromatase inhibiting imidazole derivatives
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
FI81092C (fi) * 1986-05-15 1990-09-10 Farmos Oy Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat.
US4878940A (en) * 1987-04-02 1989-11-07 Janssen Pharmaceutica N.V. Herbicidal 1,5-substituted 1H-imidazoles
IL91542A0 (en) * 1988-10-06 1990-04-29 Erba Carlo Spa N-imidazolyl-and n-imidazolyl-methyl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them
GB9127050D0 (en) * 1991-12-20 1992-02-19 Orion Yhtymae Oy Substituted imidazole derivatives and their preparation and use
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives

Also Published As

Publication number Publication date
NO981496L (no) 1998-04-02
US20020007074A1 (en) 2002-01-17
CA2231535C (en) 2005-09-20
AU7132796A (en) 1997-04-28
EE9800101A (et) 1998-10-15
PT888309E (pt) 2003-07-31
US6479530B2 (en) 2002-11-12
SI9620111A (sl) 1998-10-31
KR19990064013A (ko) 1999-07-26
BG63916B1 (bg) 2003-06-30
HUP9802927A3 (en) 2003-02-28
GB9520150D0 (en) 1995-12-06
AU708002B2 (en) 1999-07-29
CZ101898A3 (cs) 1998-09-16
HU224197B1 (hu) 2005-06-28
CZ291576B6 (cs) 2003-04-16
ES2195013T3 (es) 2003-12-01
CA2231535A1 (en) 1997-04-10
IL123721A (en) 2004-07-25
EP0888309A1 (en) 1999-01-07
HUP9802927A2 (hu) 1999-10-28
SK43998A3 (en) 1998-10-07
NO981496D0 (no) 1998-04-02
RO120409B1 (ro) 2006-01-30
JP4129891B2 (ja) 2008-08-06
CN1068592C (zh) 2001-07-18
ATE234819T1 (de) 2003-04-15
DE69626862T2 (de) 2003-12-24
PL189110B1 (pl) 2005-06-30
EP0888309B1 (en) 2003-03-19
SI9620111B (en) 2001-12-31
IL123721A0 (en) 1998-10-30
UA49847C2 (uk) 2002-10-15
LT98057A (en) 1998-09-25
NO311024B1 (no) 2001-10-01
DE69626862D1 (de) 2003-04-24
NZ319169A (en) 1999-07-29
LT4460B (lt) 1999-02-25
DK0888309T3 (da) 2003-04-22
LV12108A (lv) 1998-08-20
HK1014951A1 (en) 1999-10-08
EE04436B1 (et) 2005-02-15
RU2188194C2 (ru) 2002-08-27
CN1198741A (zh) 1998-11-11
SK283542B6 (sk) 2003-09-11
JP2000507914A (ja) 2000-06-27
US6313311B1 (en) 2001-11-06
BG102324A (en) 1999-01-29
PL328167A1 (en) 1999-01-18
WO1997012874A1 (en) 1997-04-10

Similar Documents

Publication Publication Date Title
RU2188194C2 (ru) Производные имидазола и фармацевтически приемлемая композиция
FI91857B (fi) Menetelmä terapeuttisesti aktiivisten alfa-heterosykleillä substituoitujen tolunitriilien valmistamiseksi
EP0721455B1 (fr) Tetrahydropyridine-(ou 4-hydroxypiperidine) alkylazoles ayant une activite pour les recepteurs sigma et/ou 5ht1a
SK278998B6 (sk) Deriváty imidazolu, triazolu a tetrazolu, spôsob i
NO330692B1 (no) 4-substituerte imidazol-2-tioner og imidazol-2-oner for behandling av sykdom samt anvendelse av disse for fremstilling av medikament for behandling av sykdom
EP0674626B1 (en) Selective aromatase inhibiting compounds
FI81092C (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat.
US4910212A (en) Heterocyclic compounds
Kaiser et al. Synthesis and antimuscarinic properties of some N-substituted 5-(aminomethyl)-3, 3-diphenyl-2 (3H)-furanones
JP2633087B2 (ja) 新規１−（アリールアルキルアミノアルキル）イミダゾール化合物
NL8005491A (nl) Heterocyclische verbindingen met therapeutische wer- king.
US4533670A (en) Anti-convulsant fluorenylalkylimidazole derivatives, compositions, and method of use
JP2003519688A (ja) イミダゾール誘導体